Skip to content

Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia

Comparative Study of Remimazolam, Remimazolam Plus Flumazenil vs Propofol Anesthesia on Emergence Time in Elderly Patients Undergoing Hip Replacement: A Randomized, Double Blinded Controlled Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06513923
Enrollment
136
Registered
2024-07-22
Start date
2023-02-01
Completion date
2023-10-31
Last updated
2024-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Brief summary

Purpose: This study aims to compare the emergence time among three anesthesia regimens: remimazolam, remimazolam with flumazenil, and propofol in elderly patients undergoing hip replacement surgery. Background: Previous studies have shown that flumazenil accelerates emergence time when used with remimazolam. Remimazolam and propofol have comparable emergence times, although remimazolam can be up to 5 minutes longer than propofol.

Interventions

DRUGRemimazolam

In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.

DRUGFlumazenil

Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.

DRUGPropofol

For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.

Sponsors

Central South University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Elderly patients (≥65 years old). * Scheduled for elective hip replacement surgery. * ASA (ASA, American Society of Anesthesiologists) physical status I-III. * Able to provide informed consent.

Exclusion criteria

* Known hypersensitivity to remimazolam, flumazenil, or propofol. * Severe hepatic or renal impairment. * History of benzodiazepine or alcohol abuse. * Cognitive impairment that may interfere with the ability to provide consent.

Design outcomes

Primary

MeasureTime frameDescription
Time to EmergenceWithin one day of surgeryDefined as the time from discontinuation of the anesthetic agent to the time the patient opens their eyes on verbal command.

Secondary

MeasureTime frameDescription
Hemodynamic ParametersDuring operationBlood pressure measured at various time points including diastolic and systolic blood pressure.
Post-Operative RecoveryWithin one day of surgeryAssessed using the Modified Aldrete Score.The modified Aldrete score is measured by evaluating five criteria, including the individual's activity level, respiration, circulation, consciousness, and oxygen saturation. A score of 0, 1, or 2 is given for each category, two representing the ideal condition.Given the five parameters, individuals can have a total score from zero to ten. A score lower than nine typically means the individual's status is suboptimal.
Adverse EventsWithin one day of surgeryIncidence and severity of adverse events related to anesthesia(injection pain, post-induction hypotension, bradycardia and body movement, postoperative nausea and vomiting, intraoperative awareness and delirium, sedation rescue and re-sedation).

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026